Novo Nordisk Files For Speedier Version Of NovoLog
This article was originally published in The Pink Sheet Daily
Executive Summary
Faster-acting formulation of insulin aspart represents an incremental advance over company’s flagship mealtime insulin NovoLog/NovoRapid, which is losing patent protection in the US.